GlassScriptPhysician profile
Joanna Elliott
NPI 1124419981
$1,578.19
in general payments reported to CMS, 2019-2025
22 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $84.93 · 2023: $250 · 2024: $518 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $363.16 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $139.17 | 2023-2025 | |
| Amgen INC. | $102.79 | 2023-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $74.80 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $54.60 | 2025 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $46.14 | 2024 | Qelbree |
| Phathom Pharmaceuticals, INC. | $44.83 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $40.23 | 2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Dexcom, INC. | $36.76 | 2022-2023 | Dexcom G6 Transmitter |
| Ethicon US, LLC | $31.17 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.23 | 2024 | Caplyta |
| Sk Life Science, INC. | $26.50 | 2021 | |
| Viatris Specialty LLC | $24.61 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $19.75 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $19.46 | 2025 | Omnipod |
| Genentech USA, INC. | $17.87 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.81 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $13.78 | 2021 | |
| Pfizer INC. | $13.64 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.